This report examines the current state of Australia’s rare disease policy landscape, identifying policy gaps, and provides eight recommendations aimed at ensuring all Australians living with a rare disease experience health equity. While each disease may be ‘rare’, collectively, rare diseases affect up to 8% of the Australian population.

Australia needs to modernise its health and care system to make it more sustainable, reduce cost pressures by embracing technology, lift productivity and deliver higher standards of care for all generations, according to this report. The report provides a blueprint outlining the essential steps to be taken now to ensure a healthier, more productive nation.

This report quantifies the cost of allergic disease in Australia by the economic and wellbeing impact of allergic disease on the person with allergic disease, the broader health system, the economy and the community. In 2024, it is estimated that allergic disease impacts approximately 8.2 million Australians, with an estimated total financial cost of $18.9...

The report outlines key findings for Australia from the first international survey of health outcomes and experiences of patients living with chronic conditions who are treated in GP practices. It summarises data findings across 10 health areas and outlines key insights for improving the quality of care for people living with chronic conditions.

Hypophosphatasia (HPP) is a genetic, multisystem condition that impairs the body’s ability to properly mineralise bones and teeth. Through the lens of HPP, this report illustrates how Australia’s healthcare system remains unfit for people with rare diseases. It presents a clear case for targeted, achievable reforms to improve diagnosis, treatment access and care coordination for...